A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies

Authors
Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: acec5ff6b0f2744bf5f6505cfe79d0c1157289de
First added on: Feb 14, 2025